Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antimalarial monoclonal antibodies to prevent post-discharge malaria in children with severe anaemia or severe malaria
PACTR202409607254081Phase 3Not yet recruiting
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of L9LS and dihydroartemisinin + piperaquine in malaria (2 arms), sponsored by Liverpool School of Tropical Medicine. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
L9LSdihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202409607254081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409607254081.